LSD1 Inhibitor Salts for Selective Enzyme Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for LSD1-related diseases, such as cancer, lack effective inhibitors that can selectively target and modulate LSD1 enzymes, leading to inadequate therapeutic outcomes due to LSD1's role in epigenetic regulation and its association with cancer stem cells, which makes conventional therapies less effective.
Innovation Solution
Development of 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide and its salts, which act as LSD1 inhibitors, providing pharmaceutical compositions and methods for inhibiting LSD1 enzymes to treat LSD1-related diseases by modulating its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for LSD1-related diseases, then treatment is simpler and easier to administer, but therapeutic outcomes are inadequate due to LSD1's role in epigenetic regulation and cancer stem cells
Solution Approach 1:
The invention segments the therapeutic approach by developing specific LSD1 inhibitor compounds that selectively target LSD1 enzyme activity. The compound structure is divided into specific functional groups (cyclopropylamino piperidine core with sulfonamide and cyanomethyl substituents) that enable selective inhibition of LSD1 while sparing other epigenetic regulators, thereby improving therapeutic reliability through targeted action
Solution Approach 2:
The LSD1 inhibitor compound acts as an intermediary substance that mediates between the administered drug and the LSD1 enzyme. The compound selectively binds to the LSD1 active site, forming a drug-enzyme complex that prevents substrate binding and inhibits demethylase activity, thereby achieving reliable therapeutic outcomes through specific molecular mediation
2Reliability
If LSD1 inhibitors are developed to selectively target LSD1 enzymes, then therapeutic effectiveness is improved, but the complexity of drug development and manufacturing increases
Solution Approach 1:
The invention optimizes manufacturing parameters by establishing specific reaction conditions for synthesizing the LSD1 inhibitor compound, including controlled temperature ranges, pH levels, and solvent systems. The synthesis protocol uses parameter optimization to achieve high yields and purity while simplifying downstream processing, thereby improving ease of manufacture without compromising therapeutic effectiveness
Solution Approach 2:
The invention applies local quality control by focusing manufacturing efforts on the critical functional groups of the molecule (sulfonamide, cyanomethyl, cyclopropylamino piperidine core) that determine both therapeutic effectiveness and stability. By optimizing synthesis and purification processes for these specific regions of the molecule, the invention achieves high product quality while maintaining manufacturing efficiency
Data Source
AI summary
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).